<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03684109</url>
  </required_header>
  <id_info>
    <org_study_id>20180606</org_study_id>
    <nct_id>NCT03684109</nct_id>
  </id_info>
  <brief_title>Non-invasive Glioma Characterization Through Molecular Imaging</brief_title>
  <official_title>Pilot Study for Non-invasive Glioma Characterization Through Molecular Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      MRI-based sequences can provide non-invasive quantification of intratumoral
      2-hydroxyglutarate (2HG) distribution and tumor cellularity in human gliomas and help guide
      the development of novel glioma therapies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pilot study aiming at developing and optimizing MRI-based sequences to provide
      non-invasive quantification of intratumoral 2-hydroxyglutarate (2HG) distribution and tumor
      cellularity in human gliomas and help guide the development of novel glioma therapies.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 25, 2019</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement and Comparison of in vivo vs. ex-vivo 2HG Concentration IDH-Mutant Glioma</measure>
    <time_frame>Up to 10 months</time_frame>
    <description>The primary objective is to measure and compare 2HG concentrations as measured in vivo via 3T MRI Scanner, and directly measured in the patient's surgically excised tissue sample ex vivo by tissue-based liquid chromatography-mass spectrometry (LC-MS). The primary endpoint is 2HG concentration measurement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Calculation and Correlation of Cellularity Index in IDH-Mutant Glioma</measure>
    <time_frame>Up to 10 months</time_frame>
    <description>Calculation of the cellularity index in IDH-mutant glioma in pre-surgical cases in vivo using MRI-based sequence data via 3T MRI Scanner, and the correlation of this index to formalin fixed paraffin embedded (FFPE) analysis. Samples will be described as low-moderate cellularity or high cellularity by a neuro-pathologist. Tumors of low cellularity will be characterized by the distribution of neoplastic cells singly within infiltrated brain and separated by abundant native neuroparenchyma, whereas cases designated as highly cellular are those that exhibit crowded or confluent tumor cell arrangements with scant, if any, intervening neuropil.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Glioma</condition>
  <condition>Brain Tumor</condition>
  <condition>Primary Brain Tumor</condition>
  <condition>Malignant Glioma</condition>
  <condition>Malignant Primary Brain Tumor</condition>
  <arm_group>
    <arm_group_label>IDH-Mutant Glioma Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MRI-based sequence data for 2HG quantification acquired from the image of the brain via 3T MRI scanner.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>3T MRI Scanner</intervention_name>
    <description>3T MRI image of the brain at Baseline, prior to standard-of-care surgery.</description>
    <arm_group_label>IDH-Mutant Glioma Patients</arm_group_label>
    <other_name>3 Tesla (3T) Magnetic Resonance Imaging Scanner</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults (â‰¥18 year old)

          -  Subjects with suspected or confirmed gliomas and who will have a medically indicated
             biopsy or resection of his/her brain lesion.

        Exclusion Criteria:

          -  Adults unable to consent

          -  Individuals who are not yet adults (infants, children, teenagers)

          -  Pregnant women

          -  Patients unable to have MRI done
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Macarena De La Fuente, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Macarena De la Fuente, MD</last_name>
      <phone>305-243-4951</phone>
      <email>mdelafuente@miami.edu</email>
    </contact>
    <investigator>
      <last_name>Macarena De La Fuente, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>September 21, 2018</study_first_submitted>
  <study_first_submitted_qc>September 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2018</study_first_posted>
  <last_update_submitted>February 17, 2020</last_update_submitted>
  <last_update_submitted_qc>February 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Macarena De La Fuente, MD</investigator_full_name>
    <investigator_title>Assistance Professor</investigator_title>
  </responsible_party>
  <keyword>Glioma</keyword>
  <keyword>Brain Tumor</keyword>
  <keyword>Primary Brain Tumor</keyword>
  <keyword>Malignant Primary Brain Tumor</keyword>
  <keyword>Malignant Glioma</keyword>
  <keyword>Non-invasive glioma characterization</keyword>
  <keyword>Molecular Imaging</keyword>
  <keyword>Isocitrate Dehydrogenase (IDH) Mutations</keyword>
  <keyword>MRI-Based Sequencing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

